Andy Lawton

Statistical approaches for conducting network meta‐analysis in drug development

Byron Jones, James Roger, P. W. Lane et al. · Pharmaceutical Statistics · 2011 · 54 citations

Public Health, Biostatistics, Drug Approval Processes +14

Evaluating Source Data Verification as a Quality Control Measure in Clinical Trials

Nicole Sheetz, Brett Wilson, Joanne Benedict et al. · Therapeutic Innovation & Regulatory Science · 2014 · 48 citations · Full text

Health Professions, Risk Management, Evidence-based Practice +16

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis

Delphine Bachelet, Signe Hässler, Cyprien Mbogning et al. · PLoS ONE · 2016 · 40 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results

Jenny Link, Ryan Ramanujam, Michael Auer et al. · PLoS ONE · 2017 · 39 citations · Full text

Medicine, Neurology, Pharmacology +12

Designing and incorporating a real world data approach to international drug development and use: what the UK offers

Andrew Bate, Jane Juniper, Andy Lawton et al. · Drug Discovery Today · 2015 · 33 citations · Full text

Medicine, Health Informatics, Pharmaceutical Policy +14